Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
Salt Typhoon targets telcos again with backdoor GhostSpider malware
Salt Typhoon, a Chinese state-sponsored threat actor, is using a new malware backdoor called GhostSpider to target telecommunications service providers. Cybersecurity company Trend Micro said
